RASSF1A Promoter Methylation and Kras2 Mutations in Non Small

In the present studies, we investigated the correlation between RASSF1A promoter methylation status and Kras2 mutations in 65 primary non small cell lung cancer (NSCLC) including 33 adenocarcinomas, 12 large cell carcinomas, and 20 squamous cell carcino-mas. Mutational analysis of Kras2 showed: 30 % (10 of 33) of adenocarcinomas, 25 % (3 of 12) of large cell carcinomas, and only 5 % (1 of 20) of squamous cell carcinomas contained activated Kras2 mutation at codon 12 or 13. RASSF1A promoter region CpG island methylation was detected in adenocarcinomas (55%), large cell carcinomas (25%), and squamous cell carcinomas (25%). Interestingly, combined RASSF1A methylation and Kras2 mutation data show that only f7 % adenocarcinomas/large cell carcinomas ex-hibited both KRASSF1A promoter methylation and Kras2 mutation, whereas 24 % adenocarcinomas, 50% large cell carcinomas, and 70 % squamous cell carci-nomas showed neither Kras2 mutation nor RASSF1A promoter methylation. These results showed that the majority of the primary NSCLCs with Kras2 mutations lack RASSF1A inactivation, and both RASSF1A inacti-vation and Kras2 mutation events occur frequently in adenocarcinomas and large cell carcinomas. Our results indicate a trend of inverse relationship between Kras2 activation and RASSF1A promoter methylation in the majority of human lung adenocarcinomas and large cell carcinomas